Type your tag names separated by a space and hit enter



Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.


Trade Name(s)

  • Dicetel Canadian Tradename

Ther. Class.
anti irritable bowel syndrome agents

Pharm. Class.
calcium channel blockers


  • Management of symptoms of irritable bowel syndrome (IBS) including abdominal pain, bowel disturbances and discomfort.
  • Treatment of symptoms related to biliary tract disorders.


  • Acts as a calcium channel blocker with specific selectivity for intestinal smooth muscle.
  • Relaxes gastrointestinal (mainly colon) and biliary tracts, inhibits colonic motor response to food/pharmacologic stimulation.

Therapeutic Effect(s):

Decreased symptoms of IBS.


Absorption: Poorly absorbed (1–10%).

Distribution: Distributes selectively to digestive tract.

Protein Binding: 97%.

Metabolism and Excretion: Minimal enterohepatic cycling, eliminated almost entirely in feces. Some metabolism.

Half-life: 1.5 hr.

TIME/ACTION PROFILE (blood levels)

POunknown1 hr unknown


Contraindicated in:

  • Known hypersensitivity;
  • Galactose intolerance/Lapp lactase deficiency/glucose-galactose malabsorption (tablets contain lactose);
  • Lactation:Avoid use if breast-feeding;
  • Pedi: Safety and effectiveness not established, use is not recommended.

Use Cautiously in:

  • Pre-existing eosphageal lesions/hiatal hernia (glass of water and snack should be taken with each dose);
  • OB: Should be used only if essential to welfare of patient.

Adverse Reactions/Side Effects

All less than 1%

CNS: drowsiness, headache, vertigo

GI: constipation, diarrhea, distention, dry mouth, epigastric pain/fullness, esophageal irritation, nausea

Derm: rash

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Concurrent use of anticholinergics may ↑ spasmolytic effects.


PO: (Adults) 50 mg 3 times daily; may be ↑ as needed/tolerated up to 100 mg 3 times daily.


Tablets (contain lactose): 50 mg, 100 mg


  • Assess for symptoms of IBS (abdominal pain or discomfort, bloating, constipation).
  • Assess for lactose intolerance; product contains lactose.

Potential Diagnoses

  • Acute pain
  • Diarrhea


  • PO: Administer tablet with a glass of water and food. Swallow tablet whole, do not crush, chew or suck. If >3 tablets/day prescribed, take additional tablets with glass of water and a snack. May be irritating to esophagus. Do not take the tablet while lying down or just before bedtime.

Patient/Family Teaching

  • Instruct patient to take pinaverium as directed. Take missed doses as soon as remembered unless almost time for next dose; do not double doses.
  • Caution patient to inform health care professional if the following side effects persist or worsen; stomach pain or fullness, nausea, constipation or diarrhea, heartburn, headache, dry mouth, dizziness, skin rash.
  • Instruct patient to avoid alcohol intake while taking this medication.
  • Advise female patient to inform health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

A decrease in symptoms of irritable bowel syndrome. The length of treatment depends on the condition being treated.

pinaverium is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Learn more.


Quiring, Courtney, et al. "Pinaverium." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/109859/all/pinaverium.
Quiring C, Sanoski CA, Vallerand AH. Pinaverium. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/109859/all/pinaverium. Accessed April 24, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Pinaverium. In Davis's Drug Guide. Available from https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/109859/all/pinaverium
Quiring C, Sanoski CA, Vallerand AH. Pinaverium [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 24]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/109859/all/pinaverium.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - pinaverium ID - 109859 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/109859/all/pinaverium PB - F.A. Davis Company ET - 16 DB - Medicine Central DP - Unbound Medicine ER -